CML
News
Dasatinib bests imatinib on molecular, cytogenic response rates in CML
Key clinical point: Patients with chronic myeloid leukemia who received dasatinib experienced higher rates of major molecular response and...
News
CML: T3151 plus additional mutations predicts poor response to ponatinib
Key clinical point: The third-generation tyrosine kinase inhibitor ponatinib appears to be more effective than its predecessors against certain...
News
VP Biden to AACR: Help me help you
Strengthening teamwork among researchers, sharing data, and realigning incentives for scientific breakthroughs are top strategies to advance...
News
Model used to estimate CSCs in CML
Image from UC San Diego Scientists say they have developed a model that can be used to calculate the proportion of cancer stem cells (CSCs)...
News
Targeted corticosteroids cut GVHD incidence
The key to selecting patients most likely to benefit from corticosteroid therapy is to identify those at high risk for GVHD using high levels of...
News
TKI trial leaves questions unanswered
Image by Difu Wu The phase 3 EPIC trial, a comparison of tyrosine kinase inhibitors (TKIs), has left some questions unanswered. The trial did...
News
In newly diagnosed CLL, mutation tests are advised
News
Feds advance cancer moonshot with expert panel, outline of goals
Possible opportunities include vaccine development, early-detection technology, single-cell genomic analysis, immunotherapy, a focus on pediatric...
News
Cyclophosphamide nets low rate of chronic GVHD after mobilized blood cell transplantation
Key clinical point: High-dose posttransplant cyclophosphamide is safe and effective for reducing the risk of chronic GVHD after mobilized blood...
News
High costs limit CML patients’ access to TKIs
Photo courtesy of the CDC A new study suggests that cost-sharing policies in the US create a barrier to the treatment of chronic myeloid leukemia...